Fig. 3: FR054-dependent MDA-MB-231 apoptosis is impaired by a NAGK-specific inhibitor and enhanced in shPGM3 cells. | Cell Death & Disease

Fig. 3: FR054-dependent MDA-MB-231 apoptosis is impaired by a NAGK-specific inhibitor and enhanced in shPGM3 cells.

From: Inhibition of the Hexosamine Biosynthetic Pathway by targeting PGM3 causes breast cancer growth arrest and apoptosis

Fig. 3

Cell death of MDA-MB-231 cells upon treatment with NAGKi and FR054: scheme of treatment (a), cell death determined by viable count (b), representative images of cells upon treatment (c) (4× magnification, 50 μm scale). Efficacy of shRNA silencing of PGM3 enzyme in MDA-MB-231 stable clones, as detected by RNA (d) and protein (e) levels quantification. f Cell viability of shCTR and shPGM3 clones upon 48 h treatment with FR054 0.5 mM and 1 mM. g, h Cell viability of MDA-MB-231 shCTR and shPGM3 representative clones detected by MTT test (g; 48 h FR054 at different doses) and Ann V-FITC staining (h; 48 h FR054 0.5 mM). All data represent the average ± s.d.; *p < 0.05, **p < 0.01 (Student’s t-test; comparison with FR054-not-treated sample); N = 3

Back to article page